ClinicalTrials.gg
Enrolling by invitationNCT07132749PRO-NEPAUpdated Jan 8, 2026

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

An observational study in Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd and Patients With HER2-low Advanced Breast Cancer Treated With T-DXd, sponsored by Yeon Hee Park. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Yeon Hee Park · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.

Planned enrollment
90th of 109
100 · median 444
Started
2025
with 38 others
Observational
110 of 618
30 open now
Primary completion
2026-06
later than 83 of 229 live
Registered
588th of 618
by date

Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 90th largest by planned enrollment of the 109 observational ones that give a count, is one of 39 that started in 2025, is one of 110 observational ones, reaches primary completion later than 83 of the 229 other live ones, and was the 588th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

127 more — sign in →

All 132 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 618 studies in Breast Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial is a prospective, observational, multicenter cohort study evaluating the efficacy and safety of NEPA (netupitant/palonosetron) in patients with HER2-positive or HER2-low advanced breast cancer treated with T-DXd

Read the detailed description

The observation period of this study is until the discontinuation after administration of T-Dxd or until 8 Cycle.

  • Acute phase: 0 -24 hours after T-DXd administration
  • Delayed phase: >24-120 hours after T-DXd administration
  • Overall phase: 0-120 hours after T-DXd administration
  • Long-delayed phase: >120-504 hours
  • Extended overall phase: 0-504 hours

Primary objectives: to evaluate the efficacy and safety of NEPA for CINV prevention in advanced breast cancer patients receiving at least 2 cycles of T-DXd across all defined assessment periods (acute, delayed, overall, long-delayed, and extended overall phases).

03

Conditions studied

  • Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd
  • Patients With HER2-low Advanced Breast Cancer Treated With T-DXd

Browse trials for

Keywords

  • HER2-positive
  • HER2-low
  • advanced breast cancer
  • T-DXd
  • NEPA
  • netupitant/palonosetron
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who had not been previously treated with T-DXd and are scheduled to receive their first cycle of T-DXd with NEPA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >19 years
  2. confirmed breast cancer with or locally advanced breast cancer not amenable to definitive surgery, with or without
  3. Stage IV breast cancer at initial diagnosis (de novo) or progression at distant metastatic sites following curative surgery
  4. -positive breast cancer (HER2 IHC 3+ or IHC 2+/ISH-positive) or HER2-low breast cancer (HER2 IHC 2+/ISH-negative or HER2 IHC 1+), as defined by the ASCO/CAP guidelines
  5. performance status 0-2
  6. Patients who are scheduled to initiate their first cycle of T-DXd therapy
  7. Patients who are scheduled to receive netupitant/palonosetron (NEPA) for the prevention of acute and delayed CINV according to the approved indications and dosage instructions
  8. Patients who agree to use highly effective methods or not of . Highly effective contraception methods include:

    A. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

    B. Total hysterectomy (surgical removal of the uterus and cervix) or tubal ligation (getting your "tubes tied") at least six weeks before taking study treatment.

    C. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.

    D. Combination of the following:

    I. Placement of an intrauterine device (IUD) or intrauterine system (IUS) II. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

  9. Written

Exclusion criteria

Exclusion Criteria:

  1. Patients who experienced nausea and/or vomiting within 7 days prior to the first cycle of T-DXd treatment
  2. and/or
  3. Patients with to any components of the drug or 5-HT3 receptor antagonists.
  4. Pregnant women or those suspected of being pregnant, as well as breastfeeding mothers.
  5. Any illness or condition that, in the opinion of the Investigator, may pose unwarranted risks in administering T-DXd or NEPA to the patient.
  6. Patients requiring treatment with , antiemetics, benzodiazepines, antipsychotics, or other drugs, including but not limited to pimozide, terfenadine, astemizole, cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, fluvoxamine, SSRIs, SNRIs, ritonavir, or nelfinavir.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Group 1

    advanced breast cancer patients receiving at least 2 cycles of T-DXd.

06

What researchers measure

Primary outcomes

  1. Complete response (CR: no emesis and no rescue medication)

    CR during the long-delayed phase(\>120-504 hours)

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

Secondary outcomes

  1. Complete response (CR: no emesis and no rescue medication)

    CR during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), extended overall phase (0-504 hours)

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

  2. Complete control (CC: no emesis, no rescue medication and no or mild nausea)

    CC during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours)

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

  3. Total control (TC: no emesis, no rescue medication and no nausea)

    TC during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours)

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 day), assessed up to 6 weeks

  4. No significant nausea (NSN: defined as no or mild nausea)

    NSN during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 day), assessed up to 6 weeks

  5. No nausea

    No nausea during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours)

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 day), assessed up to 6 weeks

  6. CR rate

    Daily CR rate

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

  7. NSN rate

    Daily NSN rate

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

  8. no nausea rate

    Daily no nausea rate

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

  9. Proportion of patients who receive rescue medications

    Proportion of patients who receive rescue medications

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

  10. Proportion of patients undergoing T-DXd dose delay

    Proportion of patients undergoing T-DXd dose delay due to nausea and/or vomiting

    Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks

  11. Proportion of patients requiring permanent discontinuation

    Proportion of patients requiring permanent discontinuation of T-DXd due to nausea and/or vomiting

    Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks

  12. Health-related quality of life (EQ-5D-5L)

    1. Range of EQ-5D index Minimum-Maximum Range: approx.-0.28 to -0/17 \~ 1,000 2. Range of EQ VASMinimum-Maximum Range: 0\~100 \*The higher to score, the better the health status.

    Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks

  13. FACIT Fatigue

    Proportion of patients experiencing fatigue and severity of fatigue (FACIT Fatigue) (1) Range of FACIT Fatigue scale Minimum-Maximum Range 0\~52 \*Higher score indicate less fatigue and better health status.

    Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks

  14. CTCAE v5.0

    Safety evaluated according to CTCAE v5.0, higher scores mean a worse outcome

    Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks

  15. Daily rescue medication rate

    Daily rescue medication rate

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

  16. Duration of rescue medication

    Duration of rescue medication

    Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — It will be decided later.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 10 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 20, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07132749
Lead sponsor
Yeon Hee Park
Responsible party
Yeon Hee Park (professor, Samsung Medical Center) — Sponsor-investigator
First posted
Aug 20, 2025
Start date
Aug 12, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jan 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion